GlobalData conducted a survey to assess the prospective growth in the post-pandemic DCT use.
Around 67% of the surveyed respondents, who had never used DCTs before, said that they intend to transit from traditional trials now due to the pandemic.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Is COVID-19 the Reason You Will Begin Using Decentralised Trials for the First time?
In the Rest of World (RoW) region, around 50% of the respondents highlighted COVID-19 as the biggest reason for the switch.
The figure stood at 47%, 46% and 36% in North America, Asia Pacific and Europe regions, respectively.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe analysis is based on responses received from the GlobalData, Coronavirus Survey – Pharmaceutical Imports/Exports and Supply Chain survey- fielded between 04 June 2020 to 22 June 2020.
